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Executive Summary
With an increasing variety of radiopharmaceuticals for diagnostic or therapeutic nuclear medicine as valuable diagnostic or
treatment option, radiobiology plays an important role in supporting optimizations. This comprises particularly safety and
efficacy of radionuclide therapies, specifically tailored to each patient. As absorbed dose rates and absorbed dose distributions
in space and time are very different between external irradiation and systemic radionuclide exposure, distinct radiation-induced
biological responses are expected in nuclear medicine, which need to be explored. This calls for a dedicated nuclear medicine
radiobiology. Radiobiology findings and absorbed dose measurements will enable an improved estimation and prediction of
efficacy and adverse effects. Moreover, a better understanding on the fundamental biological mechanisms underlying tumor and
normal tissue responses will help to identify predictive and prognostic biomarkers as well as biomarkers for treatment follow-up.
In addition, radiobiology can form the basis for the development of radiosensitizing strategies and radioprotectant agents. Thus,
EANMbelieves that, beyond in vitro and preclinical evaluations, radiobiologywill bring important added value to clinical studies
and to clinical teams. Therefore, EANM strongly supports active collaboration between radiochemists, radiopharmacists, radio-
biologists, medical physicists, and physicians to foster research toward precision nuclear medicine.
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Introduction
In recent years, the number of radiopharmaceuticals for diag-
nostic and therapeutic applications has increased consider-
ably. In addition, theranostics are being developed that use
the same molecular targeting platform for both imaging and
treatment. This has led to an increased medical use in both
malignant as well as benign conditions. Consequently, an im-
proved understanding of the biological processes, with special
regard to the effects of ionizing radiation to normal tissues and
tumors, is required. This is to determine the absorbed dose-
effect relationship more precisely, as a prerequisite for achiev-
ing an optimal diagnostic or therapeutic outcome. In general,
absorbed doses are low (< 20 mGy) for most organs in
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diagnostic procedures [1]. However, whenmultiple diagnostic
examinations or therapeutic applications are undertaken, this
is no longer the case. Repeated diagnostic irradiations can
result in cumulative absorbed doses in normal organs and
tissues up to a few hundred milligray [2]. For therapies,
absorbed doses can exceed previously suggested absorbed
dose limits (e.g., 23 Gy for the kidneys in peptide receptor
radionuclide therapies [3]). For absorbed doses of < 1 Gy,
stochastic effects of ionizing radiation may be observed,
whereas for therapies, a mixture of stochastic and determinis-
tic effects is expected. Radiation-related adverse effects
strongly depend on both the individual absorbed doses [4]
and the individual radiation sensitivity [5–8]. Thus, without
an individualized approach in radionuclide therapy, a group of
patients may be over-treated, jeopardizing patient safety.
Conversely, patients may be undertreated, leading to subopti-
mal treatment efficacy.
Systemic radiation delivery via radiopharmaceuticals is in-
herently different from irradiation by external radiation
sources. As a consequence, distinct radiation-induced biolog-
ical responses are expected for radiopharmaceuticals posing
considerable challenges for in vitro, preclinical and clinical
studies investigating radionuclide applications. Several re-
search topics are suggested that should be addressed with
regard to radiobiology in relation to the systemic use of radio-
pharmaceuticals and which have not yet been rigorously in-
vestigated [9–11]. Presently, there are limited studies related
to the use of radiobiology in nuclear medicine. Typical exam-
ples of such studies are provided in Table 1.
In addition, in a recent review it was stated that, for radia-
tion oncology, incomplete physics and dosimetry reporting
limits the progress of radiobiology [74]. The authors conclud-
ed that there is not only a crucial deficiency on experimental
details but also a lack of interaction between medical physi-
cists and radiobiologists. The reporting of results pertaining to
radiobiology in nuclear medicine is often provided in activi-
ties rather than absorbed doses (Table 1). Therefore, future
radiobiology studies in nuclear medicine will benefit from
including good practice of dosimetry reporting [75].
Conversely, dosimetry calculations should be based on avail-
able experimental biological data.
Consequently, in nuclear medicine, patient care optimiza-
tion principles, which include not only absorbed dose or dose
rate parameters but also radiobiological parameters, should be
integrated. To this end, close interaction and collaboration
between radiochemists, radiopharmacists, radiobiologists,
medical physicists, and physicians will be needed.
Radiobiology
Radiobiology (also known as radiation biology) is a branch of
biology concerned with the biological effects of ionizing
radiation on living organisms. Radiobiology studies the inter-
actions of ionizing radiation on atomic and molecular struc-
tures and consequently their induced effects on cells, tissues,
and organs, both normal and diseased. As such, radiobiology
enhances the understanding of biological outcome (harm or
benefit) from ionizing radiation exposure.
When ionizing radiation impinges living matter, it deposits
energy along its path leading to atomic ionization, thereby
damaging biological molecular structures (Fig. 1). In the com-
mon paradigm, DNA is considered the critical target for radi-
ation damage [76]. However, not only DNA, but also proteins,
lipids and metabolites may be modified by ionizing radiation
[77, 78]. In direct action, absorption of ionizing radiation will
happen at the site of the atoms of the cellular molecules.
Subsequent ionization events may cause breakage of chemical
bonds. It may also convert atoms and molecules into free
radicals with very reactive unpaired electrons that can further
react with neighboring molecules after which a chain of dam-
aging reactions may occur. The indirect effect from the ab-
sorption of ionizing radiation is the production of free hydrox-
yl and other highly reactive radicals, due to the hydrolysis of
water molecules. Despite their short existence, they can still
diffuse to and damage other cellular molecules. Moreover,
oxygen can create reactive oxygen or nitrogen radical species
with greater stability, longer lifetimes, and thus wider diffu-
sion possibilities [76, 78]. The abundance of these oxygen
radicals generates a condition known as oxidative stress which
can further impact cellular signaling and alter metabolic path-
ways resulting in, among others, cell death mechanisms, se-
nescence, and inflammation [78, 79]. Furthermore, ionizing
radiation can harm supramolecular structures like cellular
membranes, mitochondria, the endoplasmic reticulum, the
Golgi apparatus, the lysosomal system, and the cytoskeleton
[80]. Finally, also aspects beyond cellular boundaries are in-
creasingly being considered in radiobiology, like the tumor
microenvironment, intercellular communication, immune re-
sponses, and the abscopal effect [81, 82].
Research in radiobiology can rely on the newest techniques
and insights in biology in general and is exploiting
(epi)genomics, proteomics, metabolomics, high-throughput
screening, and exploring new models like stem cells, organoids,
in vivo orthotopic and subcutaneous patient-derived xenograft
models, or siRNA- or CRISPR/Cas9-derived models. These
are anticipated to lead to new hypotheses to understand the ef-
fects generated from ionizing radiation on biological systems and
to improve therapies based on ionizing radiation [78, 83].
Today, improved insights into the dose-response effects
caused by ionizing radiation on tumor cell killing as well as
on acute and long-term normal tissue collateral damage are
impacting greatly treatment planning in external beam radia-
tion therapy (EBRT) [83, 84]. Of several models, the linear-
quadratic (LQ) model has been best validated by experimental
and clinical data to describe cell survival fractions. The
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selection of accurate LQ parameters, α, β, and α/β, is pivotal
for a reliable estimate of radiation response. Clinically, the LQ
model is mainly used to estimate equivalent radiotherapy
schedules (e.g., calculate the equivalent dose in 2-Gy frac-
tions), but increasingly also to predict tumor control probabil-
ity (TCP) and normal tissue complication probability (NTCP)
using logistic models [76, 85]. In addition, radiobiological
discoveries are guiding clinical trials that test EBRT combined
with inhibitors of the DNA damage response and immune or
cell cycle checkpoint inhibitors. To have maximum impact for
individual patients, predictive biomarkers should be identified
that enable the rational selection of treatments to combine with
EBRT. Further research into the radiobiology of tumor me-
tabolism, cancer stem cells, and the tumor microenvironment
has the potential to translate current knowledge and future
gains to the clinic [83].
The question arises whether there is a need for a dedicated
nuclear medicine radiobiology or whether we can rely on ra-
diobiological models derived for EBRT or brachytherapy.
The response of a living system to an irradiation strongly
depends on the distribution of absorbed doses across space
and time. As these dose distributions in EBRT and brachy-
therapy are very different to those in radionuclide therapy,
extrapolation of EBRT or brachytherapy radiobiology to ra-
dionuclide therapy is not straightforward. Indeed, the specific
physical characteristics of radionuclide therapy (mixed radia-
tion qualities, time-varying and protracted exposure, low
absorbed dose rates, and inhomogeneous dose distributions)
differ from those of conventional EBRT (short exposure time,
high absorbed dose rate, and mostly homogeneous irradiation
fields) and brachytherapy (even in the low dose rate case there
is a well-defined source distribution). As a result, the re-
sponses of irradiated tissues and of the human/patient are ex-
pected to be different for radionuclide therapy [10, 86, 87].
For example, due to the time-varying and comparatively low
dose rates in radionuclide therapies, the DNA damage induc-
tion and repair may strongly differ compared to EBRT [7, 12,
13, 75]. Consequently, there is a need for the generation and
application of more radiobiological knowledge specific for
nuclear medicine diagnostic and therapeutic procedures.
Efforts to gather more evidence in radiobiology regarding
systemic exposure to ionizing radiation in nuclear medicine
applications have been increasing recently; this is illustrated in
t h i s p a r a g r a ph a t t h e ex amp l e o f [ 1 7 7Lu ]Lu -
DOTA-[Tyr3]octreotate ([177Lu]Lu-DOTA-TATE) radionu-
clide therapy in patients with advanced, progressive, somato-
statin receptor subtype (SST2)-positive midgut neuroendocrine
tumors (NETs) that was studied in the NETTER-1 phase III
trial [88]. Even though [177Lu]Lu-DOTA-TATE is clearly suc-
cessful in terms of survival benefits, current figures could be
further improved. In addition, treatment is limited by potential
adverse effects on the kidneys and the bone marrow, hindering
the use to its full potential. This emphasizes the need to further
optimize [177Lu]Lu-DOTA-TATE radionuclide therapy to fur-
ther improve efficacy while reducing toxicity. This includes
improved dosimetry hand in hand with a deep biological eval-
uation of superior radionuclides, improved SST2 ligands, in-
creased SST2 levels, the role of tumor microenvironment, and
combinations with immunotherapy, targeted therapy or DNA
modulating agents, as well as predictive markers for improved
patient selection and treatment follow-up [24, 44, 45, 89–91].
Fig. 1 Interaction of ionizing radiation with cellular matter, DNA, and
much more. DNA and other cell elements as potential targets for ionizing
radiation damage. Ionizing radiation also impacts cell signaling pathways
like oxidative stress, cell death and survival pathways, premature aging,
and inflammation, all of which moreover are highly interconnected. Also,
aspects beyond the cellular boundaries must be considered, like
intercellular communication, the tumor microenvironment, the immune
system, and the abscopal effect. Image created using BioRender.com
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Position of the EANM
Radiobiology is particularly relevant for nuclear medicine ther-
apies, as these treatments differ substantially from irradiation by
external radiation sources. This is highlighted in the common
strategic research agenda for radiation protection in medicine
[92] developed by the five medical societies involved in the
medical application of ionizing radiation, which later founded
the European Alliance for Medical Radiation Protection
Research (EURAMED) (https://www.euramed.eu/)1. An
improved understanding of the biological processes with
special regard to the effects of ionizing radiation to normal
tissues and tumors is needed to individualize the use of
existing and future developed radiopharmaceuticals. Therefore,
the radiobiological knowledge concerning the specific needs of
nuclear medicine (e.g., patient-specific and tumor-specific radi-
ation sensitivity, dose-effect relationships, spatio-temporal prop-
erties, therapy response, normal tissue effects, role of microen-
vironment and systemic reactions, combination therapies) must
be obtained and considered together with physical and medical
parameters in the development of nuclear medicine procedures.
This will also foster the principles stated in the EC Directive
2013/59/Euratom, article 56, that exposures of target volumes
in nuclear medicine treatments shall be individually planned and
their delivery appropriately verified [93]. How to interpret the
EC directive for nuclear medicine therapies is further detailed in
the recently published EANMposition paper on article 56 of the
Council Directive 2013/59/Euratom [94].
Absorbed dose measurements can be combined with radio-
biological parameters to enable an improved estimation and
prediction of efficacy and adverse effects, which can further
support treatment planning [94]. This additional input is pres-
ently, however, very rarely used, as only limited studies relat-
ed to therapeutic use of radiopharmaceuticals and including
radiobiological parameters are available. Of note, the preci-
sion dosimetry approach to describe the dose on the cellular
and subcellular level in targeted radionuclide therapy is under
development [56, 57].
In diagnostic nuclear medicine applications, especially in
longitudinal procedures, the role of radiobiology and the long-
term consequences of radiobiology-related findings, such as
reported in studies on DNA damage and repair, still has to be
defined [95–101]. Currently, these studies provide no evidence
that diagnostic nuclear medicine procedures are not safe.
Consequently, EANM believes that, to further optimize
nuclear medicine procedures for each individual patient, ef-
forts should be undertaken to promote the integration of ra-
diobiology within nuclear medicine by endorsing further
research and teaching activities. The knowledge of different
disciplines, such as biology, chemistry, medicine, pharmacy,
and physics, can then be combined for providing reproducible
results, which are, ideally, traceable to metrological standards.
Essential radiobiological studies
The nature of radiation exposure resulting from nuclear med-
icine procedures is diverse and comprises different radiation
qualities, absorbed doses, dose rates, and temporal and spatial
dose distributions [102, 103]. Low doses are encountered in
diagnostic procedures as well as from out-of-target therapeutic
exposures. High doses are expected within the tumor and in
the close proximity of the tumor during radionuclide therapy.
The determination of the absorbed dose to the tissue and on a
(sub-)cellular scale are a prerequisite for defining dose-effect
relationships, both in estimating (pre-)clinical therapy out-
come and normal tissue toxicity as well as in assessing the
cellular and molecular mechanisms, including repair capacity
(Fig. 2).
With the ambition to maximize the benefits of radiophar-
maceutical products that are effective and safe for each indi-
vidual patient, preclinical and translational science undertakes
dedicated research to understand the biological characteristics
of tumor and normal tissue intrinsic radiosensitivities and the
fundamental biological mechanisms underlying the therapeu-
tic and short- and long-term cytotoxic effects of radiopharma-
ceutical products, as well as determining the dose-effect rela-
tionship herein (Fig. 2) [9–11]. Essential aspects to investigate
related to patient- and tumor-specific radiosensitivities include
genetic background and underlying anomalies that impact ra-
diosensitivity, target distribution, tumor heterogeneity, tumor
micro-environment, and tumor growth and metastatic spread.
Important endpoints to be assessed in tumor and healthy tissue
responses are DNA damage, damage to other cell elements,
death and survival pathways, oxidative stress and inflamma-
tion, effect on the immune and systemic reactions, and repair
capacities. To this end, high-end molecular and cellular biol-
ogy tools, omics data analyses (proteomic, transcriptomic, ge-
nomic, radiomics) as well as bioimaging (microscopy, PET/
CT or SPECT/CT, autoradiography) are available. As such,
radiobiological data may reveal patient-specific radiation sen-
sitivity traits useful as predictive biomarkers of response for a
personalized radionuclide therapy regimen (e.g., genomic
traits, target level and distribution, anomalies in signaling
pathways altering radiosensitivity) as well as biomarkers use-
ful for therapy response monitoring, both on a therapeutic
aspect as well as for normal tissue damage. Radiobiological
findings may also be used as input for the development of
radiosensitizers or radioprotectant agents. Moreover, the ra-
diobiology of fractionation schemes (how many/how much
activity per fraction) as well as the radiobiology of combina-
tion therapies (combinations of radionuclide therapy with
1 EURAMED represents the European Association of Nuclear Medicine
(EANM), the European Federation of Organizations for Medical Physics
(EFOMP), the European Federation of Radiographer Societies (EFRS), the
European Society of Radiology (ESR), and the European Society for
Radiotherapy and Oncology (ESTRO).
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chemotherapy, tyrosine kinase inhibitors, immunotherapy,
hormone therapy, or radiosensitizers) [9, 25] is not well ex-
plored and could be helpful in defining optimal treatment
strategies. Finally, standardization of biological study proto-
cols as well as depositing study data in repositories is required
to allow comparison and combining of cohorts.
Some publications, regarding both external and internal
irradiation, indicate that there is a very low dose range (<
10 mGy) which shows a different dose response compared
to higher doses [99, 104–107]. Therefore, extrapolating from
higher absorbed doses and dose rates to very low doses and
dose rates is not straightforward and needs further research. It
is likely that other, different, biological responses exist after
low-dose and high-dose ionizing radiation exposure using ra-
diopharmaceuticals for both tumor and normal tissues.
Investigating low-dose radiation effects in nuclear
medicine
The linear-no-threshold (LNT) model based on the extrapola-
tion of epidemiological data at high absorbed doses is current-
ly used to estimate the risk at low doses [108], although this is
a matter of debate [109, 110]. An important aspect of the
justification of using this model is that radiation carcinogene-
sis has been assumed to be primarily driven by the damage to
the DNA and subsequent mutation of growth-regulating genes
in target cells. Yet, a number of other potential mechanisms
contributing to and modulating radiation carcinogenesis have
been proposed, including epigenetic mechanisms of gene reg-
ulation such as DNA methylation and miRNA expression,
transmissible genomic instability, bystander effects, and adap-
tive response. The extent to which these modulating effects
and non-mutational mechanisms challenge the validity of the
LNT risk extrapolation model needs to be determined. For this
purpose, the use of well-validated animal and human cellular/
tissue models of radiation carcinogenesis (both solid cancers
and leukemias) is required. In addition, also non-cancer ef-
fects (e.g., cardiovascular and neurocognitive) should be con-
sidered and studied [111].
The key question here is whether the LNT model is valid
for internal radiation exposure such as that encountered from
nuclear medicine procedures with typically low dose rates,
heterogeneous dose distributions, and a protracted nature of
exposure. Therefore, the determination of corresponding low-
dose-effect relationships can be a basis for risk assessment
also in radiation protection (ALARA, LNT hypothesis, sec-
ond cancer risk), e.g., in medical imaging or staff exposure.
To describe and monitor such effects, studies are needed to
identify biomarkers for assessing short-term or medium-/long-
term stochastic radiation risks (cancer and non-cancer) that (1)
are sufficiently sensitive in the low-dose range (< 100 mGy),
(2) are strongly linked to medium-/long-term side effects of
ionizing radiation, and (3) possess definite dose/dose rate/dose
fractionation/radiation quality dependencies.
Investigating therapeutic radiation effects in nuclear
medicine
Currently, dose-effect relations are not fully utilized in most
radionuclide therapies, as these therapies are given at a mini-
mal activity that is deemed safe in all patients and effective to
some extent. This often results in suboptimal therapy delivery.
Radioembolization therapies arguably form the exception to
this rule, as both normal liver thresholds and tumor target
Fig. 2 Contributions of radiobiology to nuclear medicine. Radiobiology
helps to understand patient- and tumor-specific radiosensitivities. In
addition, radiobiology is fundamental to a mechanistic understanding of
the therapeutic capacity of nuclear medicine agents and their potential
short- and long-term toxicities, including the dose–effect relationships
herein. Biological data will serve as input for dosimetry, together
leading to a more accurate estimation of efficacy and adverse effects.
Ideally, this will lead to patient-specific dosing schemes. Moreover,
further fundamental knowledge about the biological mechanisms
underlying tumor and healthy tissue responses will help in identifying
predictive and prognostic biomarkers as well as biomarkers for
treatment follow-up. In addition, it can form the basis for the
development of combination therapies, including radiosensitizing and
radioprotectant strategies. Image created using BioRender.com
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absorbed doses are considered as input to the treatment plan-
ning of these therapies.
More studies should be undertaken to determine TCP and
NTCP curves for specific radionuclide therapies. In this con-
text, radiobiological data (e.g., LQ α/β parameters and repair
kinetics) can serve as input for better dose-effect modeling [58,
59, 65, 70] taking into account the radiation quality, dose rate,
dose fractionation, and dose distribution on the tissue as well as
on the (sub)cellular scale [60]. Finally, results from comparison
studies with external beam radiation therapy could inform on
better treatment strategies in nuclear medicine.
Radiobiology and dosimetry should be integrated in all
stages of the development of individualized radionuclide ther-
apy drugs. Preclinical experiments should deliver the radiobio-
logical data through standardized and controlled settings with
multiple cancer models to study response variability.
Radiobiological concepts should ideally form the basis for the
design of clinical trial protocols. Phase I studies focus on safety
and thus should consider both absorbed dose and individual
patient radiosensitivity. Phase II studies should ideally be based
on absorbed dose thresholds and individual radiosensitivity. In
many cases, the choice is made for a phase II trial with fixed
activity at the maximum tolerable activity from phase I in order
to simplify the clinical protocol. However, without absorbed
doses available, it is impossible to build knowledge on dose-
effect relationships and prospective clinical trials based on in-
dividually absorbed doses are crucial [67].
Discussion
Radiobiological knowledge is not yet used in many nuclear
medicine applications, or it is used only in a basic phenome-
nological manner, such as that integrated in the model of bio-
logically effective dose (BED). This can be attributed to two
main reasons:
1. Detailed radiobiological knowledge is currently not read-
ily available, because of
a. The specifics of nuclear medicine procedures and their
multiple parameters involved (dose, dose rate, individual
DNA repair capacity, …) as well as the heterogeneity of
the conditions being treated.
b. The complexity of its integration into the clinical proce-
dures for example due to technical constraints (e.g., mi-
croscopes, bone marrow biopsies) or missing know-how.
c. The associated patient load (time per patient per
measurement).
d. The resources and costs associated (personnel, supplies,
and others).
2. The phenomenological parameters (LQ α/β parameters,
DNA repair) known from EBRT are incorrectly thought
to suffice fully for the needs of all nuclear medicine
applications.
All of the above points need to be addressed for continued
improvement of nuclear medicine procedures, including the
adequate integration of radiobiology. To solve item 1.a re-
quires intensified research as previously discussed, while item
1.b needs education and training of all involved, scientists and
physicians. Both call for the need of standardized procedures
to produce reliable data. Lastly, items 1.c and 1.d are an issue
for cost-benefit analysis which is mandatory for all medical
procedures. This applies also to item 2 whose applicability
and justification should be applied adhering to the require-
ments of best available science and cost-benefit analysis.
Thus, to develop an optimal nuclear medicine procedure
one needs to acquire and include all knowledge and appropri-
ate commitment from all involved in the process. This will
inevitably include time investment from the patient for more
measurements. Such collection of data and inclusion of a
priori knowledge is the required input for a rigorous cost-
benefit analysis. Implemented therapies will then be well
founded, both scientifically and in terms of cost and effort.
Conclusion
While the role of radiobiology for diagnostics remains to
be clarified, there is a clear role for radiobiology in opti-
mizing the benefits of therapeutic radiopharmaceuticals to
ensure that they are effective and safe for each individual
patient. Just as radiobiology data are routinely used in
EBRT treatment planning, nuclear medicine could also
benefit from a deeper integration of such data. Therefore,
there is a need to better define the dose-effect relationships
of systemic ionizing radiation for tumors as well as for
normal tissue. As absorbed dose rates and absorbed dose
distributions in space and time are very different between
external irradiation and systemic radionuclide exposure,
distinct radiation-induced biological responses are expect-
ed in nuclear medicine and need to be explored. It is ex-
pected that a better understanding of radiobiological pa-
rameters can contribute to fully exploit the capabilities of
new and existing nuclear medicine applications to be ef-
fective and safe for each individual patient. To this end, a
strong link between radiochemists, radiopharmacists, ra-
diobiologists, medical physicists, and physicians is war-
ranted to design sound study designs. In particular, the
inclusion of radiobiologists in the clinical team will be
advantageous.
Eur J Nucl Med Mol Imaging
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